All In Biotech

BLA 103780 · Serono INC

Rebif

Interferon Beta-1a · Interferon beta

Novel

Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Mar 7, 2002

Approved uses

5

Original approval plus efficacy supplements

Registered trials

165

55 Phase 3, 3 recruiting

FAERS reports

47,980

36,921 serious, 2,806 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2025.

REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Rebif is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: The mechanism(s) by which REBIF (interferon beta-1a) exerts its therapeutic effects in patients with multiple sclerosis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • REBIF · INTERFERON BETA-1A 44UG/0.5ML · SYRINGE, · Prescription
  • REBIF · INTERFERON BETA-1A 22UG/0.5ML · SYRINGE, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Interferon Beta-1a" as an intervention, any sponsor and status, largest first.

All 165 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • multiple sclerosis relapse4,095
  • fatigue2,997
  • injection site erythema2,959
  • influenza like illness2,933
  • fall2,554
  • headache2,455
  • injection site pain2,431
  • pain1,939
  • depression1,846
  • multiple sclerosis1,784
  • gait disturbance1,767
  • hypoaesthesia1,654

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004314
20051,651
2006571
20071,652
20082,032
20092,506
20103,611
20114,468
20124,809
20135,832
20143,083
20151,901
20161,806
20171,965
20181,969
20191,970
20201,537
20211,814
20221,632
20231,055
2024790
2025637
2026375

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rebif (Interferon Beta-1a/Albumin)

2024 spending

$105M

Beneficiaries

1,048

9,289 claims

Per beneficiary

$100,551

$1,768.82 per unit

View as table
YearSpending
2020$232,708,461
2021$198,665,888
2022$162,331,588
2023$131,300,521
2024$105,377,037

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 487 on PubMed

Sponsor: Serono INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.